Monographie - Vinblastine sulfate

Son güncelleme :
19/11/2024

Vinblastine sulfate

Kimyasal yapı

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Blestinib	Meksika
Cytoblastin	Malezya, Mısır
Lemblastine	Kolombiya, Meksika, Şili
Oncoblastin	Kolombiya
Uniblastin	Peru
VBlastin	Hindistan
Velbe	Avustralya, Avusturya, Birleşik Arap Emirlikleri, Büyük Britanya, Danimarka, Fas, Finlandiya, Fransa, Hollanda, İsveç, İsviçre, İtalya, Lüksemburg, Norveç, Şili, Suudi Arabistan, Yunanistan
Velblastin	Malezya, Mısır
Vinblasine	Lüksemburg
Vinblastin	Macaristan, Polonya
Vinblastina	Arjantin, Ekvador, İspanya, Kolombiya, Meksika, Peru, Romanya, Şili
Vinblastine	Amerika Birleşik Devletleri, Avustralya, Belçika, Büyük Britanya, Fransa, Hollanda, İran, İrlanda, Kanada, Suudi Arabistan, Tunus, yeni Zelanda
Vinblastinsulfat	Almanya
Vinblatine	Malezya
Vinko	Türkiye

Kaynaklar : Vinblastine sulfate

	tip	yayın
3	Dergi	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	Dergi	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Dergi	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Dergi	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
144	Dergi	Dine T, Luyckx M, Cazin JC, Goudaliez F, Mallevais ML. Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags. Int J Pharm 1991 ; 77: 279-285.
167	Dergi	Francomb MM, Ford JL, Lee MG. Adsorption of vincristine, vinblastine, doxorubicin and mitoxantrone to in-line intravenous filters. Int J Pharm 1994 ; 103: 87-92.
169	Dergi	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Dergi	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Dergi	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Dergi	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Dergi	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Dergi	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307	Dergi	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Dergi	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Dergi	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
481	Dergi	Beijnen JH, Vendrig DEMM, Underberg WJM. Stability of vinca alkaloid anticancer drugs in three commonly used infusion fluids. J Parenter Sci Technol 1989 ; 43: 84-87.
492	Dergi	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
763	Dergi	Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
827	Dergi	Black J, Buechter DD, Thurston DE. Stability of vinblastine sulfate when exposed to light. Drug Intell Clin Pharm 1988 ; 22: 634-636.
905	Dergi	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Dergi	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1009	Dergi	Black J, Buechter DD, Chinn JW, Gard J, Thurston DE. Studies on the stability of vinblastine sulfate in aqueous solution. J Pharm Sci 1988 ; 77: 630-634.
1157	Dergi	Vendrig DEMM, Smeets BPGM, Beijnen JH, van der Houwen OAGJ, Holthuis JJM. Degradation kinetics of vinblastine sulphate in aqueous solutions. Int J Pharm 1988 ; 43: 131-138.
1229	Dergi	Weir PJ, Ireland DS. Chemical stability of cytarabine and vinblastine injections. Br J Pharm Pract 1990 ; 12: 53-54, 60.
1410	Dergi	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	Dergi	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1625	Dergi	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1727	Dergi	Mittner A, Vincze Z, Jemnitz K. Stability of vinblastine sulphate containing infusions. Pharmazie 1999 ; 54: 625-626.
1953	Dergi	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
3540	Laboratuar	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3578	Laboratuar	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011
3644	Laboratuar	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010

Mentions Légales